Open-label Extension Study of Brazikumab in Crohn's Disease
Status:
Enrolling by invitation
Trial end date:
2025-04-14
Target enrollment:
Participant gender:
Summary
The purpose of Study D5271C00002 (Legacy #3150-303-008) is to permit participants in
D5271C00001 (Legacy #3150-301-008) to receive open-label brazikumab in Study D5271C00002
(Legacy #3150-303-008). This will permit long-term observation of safety in these
participants with brazikumab.